Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB has secured a SEK 50 million loan agreement with Fenja Capital II A/S, extending its financial runway into 2026 and providing the company with strategic flexibility. This non-dilutive financing strengthens Cantargia’s financial position, allowing it to continue the development of its lead programs, CAN10 and nadunolimab, which have shown promising clinical results and address significant unmet needs in their respective therapeutic areas.
More about Cantargia AB
Cantargia AB is a biotechnology company specializing in the development of antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, targeting various cancer forms and inflammatory diseases. Its oncology program focuses on nadunolimab (CAN04), which is being clinically tested primarily in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is developing CAN10, an antibody targeting autoimmune and inflammatory diseases like hidradenitis suppurativa and systemic sclerosis.
Average Trading Volume: 820,623
Current Market Cap: SEK274M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.